References
- Azemar M-D, Comperat E, Richard F, Cussenot O, Roupret M. Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: frequency, risk factors, and surveillance [review article]. UrolOncol 2011;29:130–6.
- Krogh J, Kvist E, Rye B. Transitional cell carcinoma of the upper urinary tract: prognostic variables and post-operative recurrences. Br J Urol 1991;67:32–6.
- Holmäng S, Amsler-Nordin S, Carlsson K, Holmberg E, Johansson SL. Completeness and correctness of registration of renal pelvic and ureteral cancer in the Swedish Cancer Registry. Scand J Urol Nephrol 2008;42:12–17.
- Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998;22:1435–48.
- Sobin LH, Wittekind C. TNM Classification of Malignant Tumors: Renal Pelvis and Ureter. 6th ed. New York: Wiley-Liss; 2002;196–198.
- Hermanek P, Sobin LH. Renal pelvis and ureter. In Hermanek P, Sobin LH, editors. TNM classification of malignant tumors. 4th ed. New York: Springer; 1992.
- Herr HW, Donat SM, Dalbagni G. Correlation of cystoscopy with histology of recurrent papillary tumour of bladder. J Urol 2002;168:978–80.
- Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 1998;52:594–601.
- Kang C-H, Yu T-J, Hsieh H-H, Yang JW, Shu K, Huang C-C, et al. The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract. Cancer 2003;98:1620–6.
- Holmäng S, Ströck V. Should follow-up cystoscopy after bacillus Calmette-Guérin treatment continue after five tumour-free years? Eur Urol 2012;61:503–7.
- Holmäng S, Johansson SL. Synchronous bilateral ureteral and renal pelvic carcinomas. Incidence, etiology, treatment and outcome. Cancer 2004;101:741–7.
- Holmäng S, Johansson SL. Bilateral metachronous ureteral and renal pelvic carcinomas: incidence, clinical presentation, histopathology, treatment and outcome. J Urol 2006;175:69–73.
- Oosterlinck W, Solsona E, van der Meijden APM, Sylvester R, Böhle A, Rintala E, et al. EAU guidelines on diagnosis and treatment of upper urinary tract transitional cell carcinoma. Eur Urol 2004;46:147–54.
- Roupret M, Zigeuner R, Palou J, Boehle A, Kaasinen E, Sylvester R, et al. European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur Urol 2011;59:584–94.
- Tawfiek ER, Bagley DH. Upper-tract transitional cell carcinoma. Urology 1997;50:321–9.
- Ku JH, Choi WS, Kwak C, Kim HH. Bladder cancer after nephroureterectomy in patients with urothelial carcinoma of the upper urinary tract. Urol Oncol 2011;29:383–7.
- O’Brien T, Ray E, Singh R, Coker B, Beard R; British Association of Urological Surgeons Section of Oncology. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C trial). Eur Urol 2011;60:703–10.